Effect of tranexamic acid on progress of experimental tumours and on DNA-synthesis.
The fibrinolytic inhibitor tranexamic acid affects certain experimental tumours; it prolongs survival (Lewis lung adenocarcinoma), decreases tumour weight (C3H breast carcinoma), and inhibits ascitic production (AH 130 rat hepatoma). However, it does not significantly influence DNA-synthesis in cell suspensions prepared from the same tumours.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D014148:Tranexamic Acid / Q000627:therapeutic use*
D003509:Cyclohexanecarboxylic Acids; D004273:DNA, Neoplasm; D014148:Tranexamic Acid